Current Cardiology Reports

, 15:420 | Cite as

The Evolving Role of Cardiac Troponin in the Evaluation of Cardiac Disorders

Ischemic Heart Disease (D Mukherjee, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Ischemic Heart Disease

Abstract

Due to their tissue specificity and ease of detection, the cardiac troponins (cTn) have emerged as the most important and most utilized biomarkers for the diagnosis of acute myocardial infarction (AMI). The recent achievement of greater sensitivity by cTn assay systems, however, has resulted in the detection of cTn in a wide array of medical conditions, highlighting myocardial cellular necrosis as a feature in several, seemingly unrelated medical conditions, yet complicating the interpretation of a positive test. Since elevated cTn levels are associated with worse clinical outcomes and, thereby, influence medical decisions, careful consideration should be given to the method by which these biomarkers are measured, the patient population on which the test is being applied, and applicable thresholds based on particular clinical conditions. The objective of this review is to trace the clinical evolution of the cTn biomarker from a test for AMI to a general marker of myocardial cellular necrosis with clinically important prognostic information.

Keywords

Biomarker Cardiac troponin High-sensitivity 99th percentile Myocardial necrosis Acute coronary syndrome Acute myocardial infarction Cardiotoxicity Cardiac disorders Evaluation 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Paul Anaya and David J. Moliterno declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020–35. Updated recommendations on the appropriate use of cardiac biomarkers in the evaluation of patients with suspected AMI.PubMedCrossRefGoogle Scholar
  2. 2.
    Bandman E. Contractile protein isoforms in muscle development. Dev Biol. 1992;154:273–83.PubMedCrossRefGoogle Scholar
  3. 3.
    US National Library of Medicine. Genetics Home Reference. Available at: http://ghr.nlm.nih.gov/gene. Accessed March 2012.
  4. 4.
    Jaffe AS, Vasile VC, Milone M, et al. Diseased skeletal muscle: a non cardiac source of increased circulating concentrations of cardiac troponin T. JACC. 2011;58:1819–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Katus HA. Development of the cardiac troponin T immunoassay. Clin Chem. 2008;54:1576–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58:54–61.PubMedCrossRefGoogle Scholar
  7. 7.
    Apple FS, Jesse RL, Newby K, Wu AHB, Christenson RH. National academy of clinical biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem. 2007;53:547–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Kavsak PA, MacRae AR, Yerna M-J, Jaffe AS. Analytic and clinical utility of a next-generation, highly sensitive cardiac troponin I assay for early detection of myocardial injury. Clin Chem. 2009;55:573–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Apple FS. A new season for cardiac troponin assays: it’s time to keep a scorecard. Clin Chem. 2009;55:1303–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Scharnhorst V, Krasznai K, van’t Veer M, Michels RH. Variation of cardiac troponin I and T measured with sensitive assays in emergency department patients with noncardiac chest pain. Clin Chem. 2012;58:1208–14.PubMedCrossRefGoogle Scholar
  11. 11.
    Cardinaels EPM, Mingels AMA, Jacobs LHJ, et al. A comprehensive review of upper reference limits reported for (high-)sensitivity cardiac troponin assays: the challenges that lie ahead. Clin Chem Lab Med. 2012;50:791–806.PubMedCrossRefGoogle Scholar
  12. 12.
    Normann J, Mueller M, Biener M, et al. Effect of older age on diagnostic and prognostic performance of high sensitivity troponin T in patients presenting to an emergency department. Am Heart J. 2012;164:698–705.PubMedCrossRefGoogle Scholar
  13. 13.
    Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Circulation. 2007;116:2634–53.PubMedCrossRefGoogle Scholar
  14. 14.
    Apple FS, Parvin CA, Buechler KF, et al. Validation of the 99th percentile cut-off independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction. Clin Chem. 2005;51:2198–200.PubMedCrossRefGoogle Scholar
  15. 15.
    Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113:1958–65.PubMedCrossRefGoogle Scholar
  16. 16.
    Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. NEJM. 2009;361:868–77.PubMedCrossRefGoogle Scholar
  17. 17.
    Biener M, Mueller M, Vafaie M, et al. Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in a unselected emergency department population. Int J Cardiol. 2012. doi: 10.1016/j.ijcard.2012.09.122.PubMedGoogle Scholar
  18. 18.
    Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation. 2003;108:2543–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Morrow DA, Cannon CP, Jesse RL, et al. National academy of clinical biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem. 2007;53:552–74.PubMedCrossRefGoogle Scholar
  20. 20.
    Giannitsis E, Becker M, Kurz K, et al. High sensitivity cardiac troponin T for early prediction of evolving non-ST-elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem. 2010;56:642–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Mueller MJ, Blener M, Vafale M, et al. Absolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndrome and in patients with increased troponin in the absence of acute coronary syndrome. Clin Chem. 2012;58:209–18.PubMedCrossRefGoogle Scholar
  22. 22.
    Apple FS, Pearce LA, Smith SW, Kaczmarek JM, Murakami MAM. Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events. Clin Chem. 2009;55:930–7.PubMedCrossRefGoogle Scholar
  23. 23.
    • Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation. 2011;124:136–45. One of the earliest demonstrations of the superiority of following absolute changes in cTn concentration over relative changes for the early detection of AMI.PubMedCrossRefGoogle Scholar
  24. 24.
    MacRae AR, Kavsak PA, Lustig V, et al. Assessing the requirement for for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies. Clin Chem. 2006;52:812–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Haaf P, Drexler B, Reichlin T, et al. High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation. 2012;126:31–40.PubMedCrossRefGoogle Scholar
  26. 26.
    • Reiter M, Twerenbold R, Reichlin T, et al. Early diagnosis of acute myocardial infarction in patients with pre-existing coronary artery disease using more sensitive cardiac troponin assays. Eur Heart J. 2012;33:988–97. A substudy of the APACE population showing the utility of cTn in detecting AMI in patients with underlying CAD. Depending on the brand of high-sensitive cTn assay used, slightly different cut-off values defining an abnormal cTn level were derived for patients with, versus without CAD, although considerable overlap was noted. Nevertheless, high-sensitive cTn assays performed better than conventional assays in diagnosing AMI early, thereby retaining their prognostic value regardless of the presence of CAD.PubMedCrossRefGoogle Scholar
  27. 27.
    Gassenmaier T, Buchner S, Birner C, et al. High-sensitive troponin I in acute cardiac conditions: implications of baseline and sequential measurements for diagnosis of myocardial infarction. Atherosclerosis. 2012;222:116–22.PubMedCrossRefGoogle Scholar
  28. 28.
    Khan NA, Hemmelgarn BR, Tonelli M, Thompson CR, Levin A. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation. 2005;112:3088–96.PubMedCrossRefGoogle Scholar
  29. 29.
    • Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. JACC. 2012;60:2427–63. An excellent document summarizing data on the appropriate use of cardiac troponin testing in cardiac conditions, including answers to frequently asked questions regarding cardiac troponin, its role in the diagnosis of AMI, and its interpretation.PubMedCrossRefGoogle Scholar
  30. 30.
    Alyanakian M-A, Dehoux M, Chatel D, et al. Cardiac troponin I in diagnosis of perioperative myocardial infarction after cardiac surgery. J Cardiothorac Vasc Anesth. 1998;12:288–94.PubMedCrossRefGoogle Scholar
  31. 31.
    Soraas CL, Friis C, Engebretsen KVT, et al. Troponin T is a better predictor than creatine kinase-MB of long-term mortality after coronary artery bypass graft surgery. Am Heart J. 2012;164:779–85.PubMedCrossRefGoogle Scholar
  32. 32.
    Buse GAL, Koller MT, Grapow M, et al. 12-Month outcome after cardiac surgery: prediction by troponin T in combination with the European system for cardiac operative risk evaluation. Ann Thorac Surg. 2009;88:1806–13.CrossRefGoogle Scholar
  33. 33.
    Domanski MJ, Mahaffey K, Hasselblad V, et al. Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA. 2011;305:585–91.PubMedCrossRefGoogle Scholar
  34. 34.
    Buse GAL, Koller MT, Grapow M, et al. The prognostic value of troponin release after adult cardiac surgery – a meta analysis. European J Cardio-thoracic Surg. 2010;37:399–406.Google Scholar
  35. 35.
    • Daaman P, Wallentin L, Fox KAA, et al. Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 trials. Circulation. 2012;125:568–76. A study analyzing data on peri-procedural MI events from three well known large, prospective, randomized trials primarily enrolling high risk patients with CAD. This was mostly a study of peri-PCI AMI as the number of patients undergoing CABG was only 21 as compared to 176 undergoing PCI. The analysis confirms earlier data suggesting no significant impact on CV mortality related to the occurrence of peri-PCI MI.CrossRefGoogle Scholar
  36. 36.
    Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. JACC. 1998;31:241–51.PubMedCrossRefGoogle Scholar
  37. 37.
    Zimarino M, Affinito V. The prognosis of periprocedural myocardial infarction after percutaneous coronary interventions. Cardiovasc Revasc Med. 2013;14:32–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary intervention creatinine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol. 2004;93:18–23.PubMedCrossRefGoogle Scholar
  39. 39.
    Novack V, Pencina M, Cohen DJ, Kleiman NS, Yen C-H, et al. Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med. 2012;172:502–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Vranckx P, Farooq V, Garg S, et al. Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting. Heart. 2012;98:1424–30.PubMedCrossRefGoogle Scholar
  41. 41.
    Nageh T, Sherwood RA, Harris BM, Thomas MR. Prognotic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease. Heart. 2005;91:1181–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Mohammed AA, Januzzi Jr JL. Clinical applications of highly sensitive troponin assays. Cardiol Rev. 2010;18:12–9.PubMedCrossRefGoogle Scholar
  43. 43.
    De Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. Am Heart J. 2012;163:821–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Martinez-Rumayor AA, De Lemos JA, Rohatgi AK, et al. Addition of highly sensitive troponin T and N-terminal pro-B-type natriuretic peptide to electrocardiography for detection of left ventricular hypertrophy: results from the Dallas Heart Study. Hypertension. 2013;61:105–11.PubMedCrossRefGoogle Scholar
  45. 45.
    Neeland IJ, Drazner MH, Berry JD, et al. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. JACC. 2013;61:187–95.PubMedCrossRefGoogle Scholar
  46. 46.
    Imazio M, Demichelis B, Cecchi E, et al. Cardiac troponin I in acute pericarditis. JACC. 2003;42:2144–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Chalela JA, Ezzeddine MA, Davis L, Warach S. Myocardial injury in acute stroke – a troponin I study. Neurocrit Care. 2004;3:343–6.CrossRefGoogle Scholar
  48. 48.
    Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ. 2005;173:1191–202.PubMedCrossRefGoogle Scholar
  49. 49.
    • Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary vs noncoronary disease. Eur Heart J. 2011;32:404–11. Excellent review on the occurrence of myocardial necrosis in non-ischemic cardiac conditions.PubMedCrossRefGoogle Scholar
  50. 50.
    Garg R, Singh A, Khaja A, Martin A, Aggarwal K. How does volume status affect BNP and troponin levels as markers of cardiovascular status in peritoneal dialysis? Congest Heart Fail. 2009;15:240–4.PubMedCrossRefGoogle Scholar
  51. 51.
    Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13:699–709.PubMedCrossRefGoogle Scholar
  52. 52.
    Yoon GJ, Telli ML, Kao DP, et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies. Are clinicians responding optimally? JACC. 2010;56:1644–50.PubMedCrossRefGoogle Scholar
  53. 53.
    Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749–54.PubMedCrossRefGoogle Scholar
  54. 54.
    Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107:1375–80.PubMedCrossRefGoogle Scholar
  55. 55.
    Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy induced cardiotoxicity. Systematic review of the literature and recommendations for use. Am J Pathol. 2008;130:688–95.Google Scholar
  56. 56.
    Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474–81.PubMedCrossRefGoogle Scholar
  57. 57.
    •• Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. JACC. 2010;55:213–20. An important study building on previous work by this group and others emphasizing the importance of monitoring cardiotoxicity in response to chemotherapy using cTn as an early marker of myocardial injury to guide medical decisions regarding early medical interventions to prevent or treat LV dysfunction.PubMedCrossRefGoogle Scholar
  58. 58.
    Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta analysis. Circulation. 2007;116:427–33.PubMedCrossRefGoogle Scholar
  59. 59.
    Jimenez D, Uresandi F, Otero R, et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest. 2009;136:974–82.PubMedCrossRefGoogle Scholar
  60. 60.
    Walter T, Aphaltrer P, Weilbacher F, et al. Predictive value of high-sensitivity troponin I and D-dimer assays for adverse outcome in patients with acute pulmonary embolism. Exp Ther Med. 2013;5:5860590.Google Scholar
  61. 61.
    Ferrari E, Moceri P, Crouzet C, Doyen D, Cerboni P. Timing of troponin I measurement in pulmonary embolism. Heart. 2012;98:732–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Lankeit M, Jimenez D, Kostrubiec M, Dellas C, Hasenfuss G, et al. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation. 2011;124:2716–24.PubMedCrossRefGoogle Scholar
  63. 63.
    Jung SK, Kim WY, Sohn CH, Kang HD, Oh SH, et al. Value of cardiac troponin I for predicting in-hospital occurrence of hypotension in stable patients with acute pulmonary embolism. Shock. 2013;39:50–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Cardiovascular Medicine, Gill Heart InstituteUniversity of KentuckyLexingtonUSA

Personalised recommendations